Primary and secondary efficacy end points
SECONDARY
The mean number of coagulations (the primary efficacy end point) determined by the third-party evaluation committee was significantly higher in the control group (4.9 ± 5.2) than in the TDM-621 group (1.0 ± 1.4) (Effect of TDM-621 on the number of cauterizations with hemostats (PPS). Data are provided as mean ± SD. *Other secondary efficacy end points (PPS)Table Hemostasis condition in the TDM-621 group (PPS)